Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 9/20 | 0.45 |
| ▸ | NPEPPS | P55786 | 6/20 | 0.45 |
| ▸ | ANPEP | P15144 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29313524 | 0.86 | LMNA (0.58) | LMNAADORA2AADORA2BNPEPPSANPEP | |
| SCHEMBL26554333 | 0.84 | LMNA (0.59) | LMNAADORA2AADORA2BNPEPPSANPEP | |
| SCHEMBL17032321 | 0.83 | LMNA (0.62) | LMNAADORA2AADORA2BNPEPPSANPEP | |
| SCHEMBL26808463 | 0.81 | LMNA (0.55) | LMNAADORA2AADORA2BNPEPPSANPEP | |
| SCHEMBL31160178 | 0.79 | LMNA (0.79) | LMNAADORA2AADORA2BNPEPPSANPEP | |
| SCHEMBL20482906 | 0.79 | LMNA (0.64) | LMNAADORA2AADORA2BNPEPPSANPEP | |
| SCHEMBL31160186 | 0.79 | LMNA (0.66) | LMNAADORA2AADORA2BNPEPPSANPEP | |
| SCHEMBL12799299 | 0.79 | LMNA (0.72) | LMNAADORA2AADORA2BP2RY12NPEPPS | |
| SCHEMBL26808236 | 0.78 | LMNA (0.52) | LMNAADORA2AADORA2BNPEPPSANPEP | |
| SCHEMBL26808216 | 0.78 | LMNA (0.52) | LMNAADORA2AADORA2BNPEPPSANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180135054-A1 | MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE | NSUN2, ADAR, POLM | LMNA 808/4885ADORA2A 1005/4885ADORA2B 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.